Two major developments in prescription drug pricing are making headlines. One is the federal rollout of TrumpRx, a consumer-facing drug pricing website. The other is a landmark FTC settlement with Express Scripts, one of the country’s largest pharmacy benefit managers (PBMs).
For employers, these announcements have raised understandable questions. Do these developments change how pharmacy benefits should be designed or managed? Do they signal meaningful cost relief, or are they largely symbolic?
The answer is nuanced. While both developments reflect growing pressure on drug pricing, their implications for employer-sponsored health plans are very different. Understanding that distinction is critical to avoid overreaction on one hand and complacency on the other.
What Is TrumpRx?
TrumpRx.gov is a federal, direct-to-consumer prescription drug pricing website launched in early February 2026. It lists a limited set of medications and directs users to manufacturer or discount purchase options where they can buy drugs at advertised cash prices. The federal government does not sell drugs through the site.
TrumpRx emerged amid increasing public frustration with high list prices, opaque rebate structures, and the slow pace of traditional drug pricing reform. The platform was designed to offer immediate, highly visible price relief for select medications by bypassing traditional pharmacy benefit channels.
At launch, TrumpRx included approximately 43 medications, largely brand-name drugs used to treat conditions such as diabetes, obesity, and infertility.
Several points are important for employers to understand:
- TrumpRx pricing is cash-only and generally sits outside employer health plans, meaning purchases do not count toward deductibles or out-of-pocket maximums.
- For many insured patients, existing plan pricing is often lower than TrumpRx cash prices, particularly when generics or preferred formulary options are available.
- Many drugs included on the platform already have lower-cost generic or alternative discount options available through current benefit designs.
This cash-only structure creates an important consideration for employers. While off-benefit pricing may reduce immediate out-of-pocket costs for certain individuals, prescriptions filled outside the benefit do not count toward deductibles or out-of-pocket maximums and may not be captured in plan claims data. That can affect care coordination, utilization management, and overall visibility into pharmacy trends. For employers, the question is not simply whether a price is lower, but whether that pricing sits inside or outside the benefit structure.
In practice, TrumpRx does not fundamentally change drug pricing economics. It centralizes and publicizes manufacturer cash pricing that, in many cases, already exists through other direct-to-consumer channels.
For employers using traditional, rebate-driven PBM arrangements, the platform may surface lower cash prices for certain drugs that were not previously emphasized within standard benefit communications. It may also provide an option for employees without coverage for therapies such as weight loss medications or fertility treatments, where off-benefit pricing could reduce out-of-pocket exposure.
However, for employers already using transparent or pass-through PBM models that prioritize lowest net drug cost within the benefit, TrumpRx is unlikely to materially change plan economics. In those cases, the underlying pricing strategy already focuses on minimizing net cost rather than maximizing rebates, limiting incremental impact.
Overall, TrumpRx is most likely to benefit uninsured or underinsured individuals and remains of limited relevance for most employer-sponsored health plans because it does not integrate with traditional insurance benefits.
What Is the FTC Settlement With Express Scripts?
In February 2026, the Federal Trade Commission secured a landmark settlement with Express Scripts, the PBM within Evernorth and Cigna, resolving allegations that certain PBM practices contributed to inflated insulin prices and higher patient out-of-pocket costs.
According to the FTC, the settlement requires Express Scripts to implement a series of changes intended to improve transparency and better align pricing with patient costs. These changes include:
- Ending formulary practices that favor higher list-price drugs over lower net-cost alternatives
- Offering benefit designs where member cost sharing reflects net drug prices, rather than inflated list prices
- Expanding reporting and transparency to plan sponsors
- Reducing PBM compensation structures tied to rebates and list pricing
- Making direct-to-consumer pricing options, such as TrumpRx, available within standard offerings where legally permissible
The FTC estimates that these reforms could reduce patient out-of-pocket costs by billions of dollars over time, particularly for insulin and other high-utilization therapies.
While the settlement focuses heavily on insulin pricing, its broader significance lies in the precedent it sets for how PBM pricing practices may be evaluated across other drug classes over time.
This settlement also follows a broader FTC investigation into PBM practices across the industry. CVS Caremark and OptumRx, the other two largest PBMs, remain under regulatory scrutiny, and potential outcomes for those organizations are still to be determined.
This broader context helps explain why TrumpRx and the FTC settlement are often discussed together. TrumpRx surfaces cash prices outside the benefit, while the FTC settlement challenges how PBMs determine which prices and purchasing channels are recognized as in-network within employer-sponsored pharmacy benefits.
If regulators ultimately require PBMs to recognize certain direct-to-consumer prices within standard benefits, platforms like TrumpRx could move from a headline-driven cash option to something that meaningfully intersects with employer benefit design. That outcome is possible, but not guaranteed, and would unfold over time.
For this shift to materially affect employer pharmacy spend, several conditions would need to be met. Direct-to-consumer pricing would need to be recognized within insurance benefits, aligned with deductibles and out-of-pocket maximums, and incorporated into standard PBM or carrier contracting models. None of these changes are in place today, and any movement in this direction would likely require additional regulatory guidance and employer opt-in.
What This Means for Employers Right Now
TrumpRx does not reduce plan costs, premiums, or overall employer pharmacy spend today. For many insured employees, existing plan pricing remains less expensive than TrumpRx cash pricing, particularly where generics and preferred formulary options are available.
Employers should consider not only whether an individual price appears lower, but how off-benefit purchasing affects claims visibility, care coordination, and overall pharmacy trend analysis.
For employers already using transparent PBM models that prioritize lowest net cost, TrumpRx is unlikely to change plan economics today, reinforcing that its primary value is visibility rather than benefit integration.
The FTC and Express Scripts settlement, while more technical, is potentially more consequential for employers. It signals increased regulatory scrutiny of PBM pricing practices that directly affect formularies, rebate economics, transparency, and how member cost sharing is calculated.
The relevance of these developments may also vary by funding arrangement, with self-funded employers generally having more flexibility to evaluate future benefit design changes than fully insured employers, where carrier adoption and regulatory approval play a larger role.
Employers should view these developments as a moment for awareness and preparation, not immediate benefit redesign.
What Employers Should Do Now
Employers do not need to overhaul pharmacy benefits in response to these headlines. However, there are practical steps that can help protect plan value and avoid confusion:
Set clear expectations internally and with employees.
Communicate that TrumpRx is a cash-pay pricing option outside the benefit and does not automatically lower premiums or employer costs.
Ask targeted questions of PBM partners
During renewals or performance reviews, ask how formularies account for lower net-cost alternatives, whether member cost sharing reflects net pricing, and how transparency commitments align with evolving regulatory expectations.
Identify limited cases where off-benefit pricing may help, while evaluating potential tradeoffs in claims visibility and care coordination
Certain populations with high out-of-pocket specialty drug costs may benefit from cash pricing options. These cases should be evaluated deliberately and in coordination with advisors.
Prepare for potential future integration without assuming it
If direct-to-consumer pricing becomes recognized within in-network benefits, employers will need to understand how those prices interact with deductibles, out-of-pocket maximums, and total plan costs.
Bottom Line
TrumpRx is a highly visible direct-to-consumer pricing initiative that does not currently integrate with employer-sponsored benefits and has limited immediate impact on overall plan economics.
The FTC and Express Scripts settlement represents a more structural shift. It signals potential changes in how PBM pricing practices, network recognition, and benefit design may evolve over time.
This is not an endorsement of any specific policy or platform. It is an assessment of how emerging regulatory and pricing dynamics could influence employer pharmacy strategy.
For employers, the priority is not reacting to headline pricing, but understanding how pricing sits inside or outside the benefit structure and ensuring pharmacy programs remain aligned with cost discipline, access, and long-term sustainability as the landscape evolves.




